And WOOM RESTRICT		Document No.	IITB/IEC/ICF-A/2023
$\mathcal{E}(\mathcal{A})$	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
and and age		Page No.	Page 1 of 8

#### Please delete the instructions marked in BLUE before submitting the proposal for review

#### Notes to Researchers:

- 1. Please note that this is a template developed by the WHO ERC to assist the Principal Investigator in the design of their informed consent forms (ICF). It is important that Principal Investigators adapt their own ICFs to the outline and requirements of their particular study.
- 2. The informed consent form consists of two parts: the information sheet and the consent certificate.
- 3. This template includes examples of key questions that may be asked at the end of each section that could ensure the understanding of the information being provided, especially if the research study is complex. These are just examples, and suggestions, and the investigators will have to modify the questions depending upon their study.
- 4. Please do not delete any sections. If any portion is not relevant to your study, please mark it as NA.
- 5. ICF should be drafted in simple language (language used throughout form should be at the level of a local student of class 6th/8th) English, Hindi and other vernacular languages as applicable

**TEMPLATE ON FOLLOWING PAGE...** 

And WOOM NEXTERNA		Document No.	IITB/IEC/ICF-A/2023
$\{(\mathbf{x})\}$	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
	Page No.	Page 2 of 8	

## Informed Consent Form for \_\_\_\_\_ [Study Title]

## Please delete the instructions marked in BLUE before submitting the proposal for review

Name the group of individuals for whom this informed consent form is written. Because research for a single project is often carried out with a number of different groups of individuals - for example healthcare workers, patients, and parents of patients - it is important that you identify which group this particular consent is for.

#### Name of Principal Investigator

#### Name of Organization

Name of Sponsor

Name of Proposal

This Statement of Consent consists of two parts:

- Information Sheet (to share information about unused samples with you)
- Certificate of Consent (to record your agreement)

You will be given a copy of the full Statement of Consent

## **PART I: Information Sheet**

## I. Introduction

Briefly state who you are and explain that you are inviting them to participate in the research you are doing.

**II. Purpose of the research** Explain in layman terms why you are doing the research.

## III. Type of Research Intervention

Briefly state the type of intervention that will be undertaken. This will be expanded upon in the procedures section.

## **IV.** Participant selection

State why this participant has been chosen for this research. People often wonder why they have been chosen to participate and may be fearful, confused or concerned.

at wown me tring a		Document No.	IITB/IEC/ICF-A/2023
	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
Section and		Page No.	Page 3 of 8

## V. Voluntary Participation

Indicate clearly that they can choose to participate or not. State, what the alternative - in terms of the treatment offered by the clinic - will be, if they decide not to participate. State, only if it is applicable, that they will still receive all the services they usually do whether they choose to participate or not.

## VI. Include the following section only if the protocol is for a clinical trial:

## A. Information on the Trial Drug [Name of Drug]

1) give the phase of the trial and explain what that means. Explain to the participant why you are comparing or testing the drugs.

2) provide as much information as is appropriate and understandable about the drug such as its manufacturer or location of manufacture and the reason for its development.

3) explain the known experience with this drug

4) explain comprehensively all the known side-effects/toxicity of this drug, as well as the adverse effects of all the other medicines that are being used in the trial

## **B. Procedures and Protocol**

Describe or explain the exact procedures that will be followed on a step-by-step basis, the tests that will be done, and any drugs that will be given. Explain from the outset what some of the more unfamiliar procedures involve (placebo, randomization, biopsy, etc.) Indicate which procedure is routine and which is experimental or research. Participants should know what to expect and what is expected of them. Use active, rather than conditional, language. Write "we will ask you to...." instead of "we would like to ask you to...."

In this template, this section has been divided into two: firstly, an explanation of unfamiliar procedures and, secondly, a description of process.

#### a) Unfamiliar Procedures

This section should be included if there may be procedures which are not familiar to the participant.

## • If the protocol is for a **clinical trial**:

1) involving randomization or blinding, the participants should be told what that means and what chance they have of getting which drug (i.e. one in four chances of getting the test drug).

2) involving an inactive drug or placebo, it is important to ensure that the participants understand what is meant by a placebo or inactive drug.

And WOUN DESTROY		Document No.	IITB/IEC/ICF-A/2023
$\{(\mathbb{Z})\}$	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
and said spin		Page No.	Page 4 of 8

3) which may necessitate a rescue medicine, then provide information about the rescue medicine or treatment such as what it is and the criterion for its use. For example, in pain trials, if the test drug does not control pain, then intravenous morphine may be used as a rescue medicine.

#### • If the protocol is for **clinical research**:

Firstly, explain that there are standards/guidelines that will be followed for the treatment of their condition. Secondly, if as part of the research a biopsy will be taken, then explain whether it will be under local anesthesia, sedation or general anesthesia, and what sort of symptoms and side effects the participant should expect under each category.

#### • For any **clinical study** (if relevant):

If blood samples are to be taken explain how many times and how much in a language that the person understands. It may, for example, be inappropriate to tell a tribal villager that blood equal to a wine-glass full will be taken but it may be very appropriate to use pictures or other props to illustrate the procedure if it is unfamiliar.

If the samples are to be used only for this research, then explicitly mention here that the biological samples obtained during this research procedure will be used only for this research, and will be destroyed after \_\_\_\_\_ years, when the research is completed. If the tissues/blood samples or any other human biological material will be stored for a duration longer than the research purpose, or is likely to be used for a purpose other than mentioned in the research proposal, then provide information about this and obtain consent specifically for such storage and use in addition to consent for participation in the study - (see last section)

#### b) Description of the Process

Describe to the participant what will happen on a step-by-step basis.

#### VII. Duration


Include a statement about the time commitments of the research for the participant including both the duration of the research and follow-up, if relevant.

#### VIII. Side Effects

Potential participants should be told if there are any known or anticipated side effects and what will happen in the event of a side effect or an unexpected event.

#### IX. Risks

Explain and describe any possible or anticipated risks. Describe the level of care that will be available in the event that harm does occur, who will provide it, and who will pay for it. A risk can



be thought of as being the possibility that harm may occur. Provide enough information about the risks that the participant can make an informed decision.

## X. Benefits

Mention only those activities that will be actual benefits and not those to which they are entitled regardless of participation. Benefits may be divided into benefits to the individual, benefits to the community in which the individual resides, and benefits to society as a whole as a result of finding an answer to the research question.

## XI. Reimbursements

State clearly what you will provide the participants with as a result of their participation. WHO does not encourage incentives. However, it recommends that reimbursements for expenses incurred as a result of participation in the research be provided. These may include, for example, travel costs and money for wages lost due to visits to health facilities. The amount should be determined within the host country context.

## XII. Confidentiality

Explain how the research team will maintain the confidentiality of data, especially with respect to the information about the participant which would otherwise be known only to the physician but would now be available to the entire research team.

# XIII. Sharing the Results

Where it is relevant, your plan for sharing the information with the participants should be provided. If you have a plan and a timeline for the sharing of information, include the details. You should also inform the participant that the research findings will be shared more broadly, for example, through publications and conferences.

# XIV. Right to Refuse or Withdraw

This is a reconfirmation that participation is voluntary and includes the right to withdraw. Tailor this section to ensure that it fits for the group for whom you are seeking consent. The example used here is for a patient at a clinic.

# XV. Alternatives to Participating

Include this section only if the study involves administration of investigational drugs or use of new therapeutic procedures. It is important to explain and describe the <u>established</u> standard treatment.

# XVI. Who to Contact

Provide the name and contact information of someone who is involved, informed and accessible (a local person who can actually be contacted. State also that the proposal has been approved and how.

And MOUN MENTING		Document No.	IITB/IEC/ICF-A/2023
$\frac{1}{2}$	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
and and and		Page No.	Page 6 of 8

XVII. This proposal has been reviewed and approved by IIT Bombay Institute Ethics Committee (IEC), which is a committee whose task it is to make sure that research participants are protected from harm. If you wish to find about more about the IEC, contact IEC Member secretary, Dr. Sreelekha P. Gopinathan, Technical Officer, IRCC at iec@ircc.iitb.ac.in

A WOM REPUER		Document No.	IITB/IEC/ICF-A/2023
	<u>Informed Consent Form Template</u> <u>For Clinical Studies</u>	Revision No.	1
for a rate above	Page No.	Page 7 of 8	

#### **PART II: Certificate of Consent**

This section should be written in the first person and have a statement similar to the one in bold below. If the participant is illiterate but gives oral consent, a witness must sign. A researcher or the person going over the informed consent must sign each consent along with the PI. The certificate of consent should avoid statements that have "I understand...." phrases. The understanding should perhaps be better tested through targeted questions during the reading of the information sheet (some examples of questions are given above), or through the questions being asked at the end of the reading of the information sheet, if the potential participant is reading the information sheet him/herself.

I have read the foregoing information, or it has been read to me. I have had the opportunity to ask questions about it and any questions that I have asked have been answered to my satisfaction. I consent voluntarily to participate as a participant in this research.

Print Name of Participant\_\_\_\_\_

Signature of Participant \_\_\_\_\_

Date \_\_\_

Day/month/year

#### If illiterate

A literate witness must sign (if possible, this person should be selected by the participant and should have no connection to the research team). Participants who are illiterate should include their thumb-print.

I have witnessed the accurate reading of the consent form to the potential participant, and the individual has had the opportunity to ask questions. I confirm that the individual has given consent freely.

AND

Print name of witness	
-----------------------	--


Signature of witness \_\_\_\_\_

Date \_\_

Day/month/year

Thumb print of participant





## Statement by the researcher/person taking consent

I have accurately read out the information sheet to the potential participant, and to the best of my ability made sure that the participant understands the requirements of the study as outlined in the Information Sheet.

I confirm that the participant was given an opportunity to ask questions about the study, and all the questions asked by the participant have been answered correctly and to the best of my ability. I confirm that the individual has not been coerced into giving consent, and the consent has been given freely and voluntarily.

A copy of this ICF has been provided to the participant.

Print Name of Researcher/person taking the consent\_\_\_\_\_

Signature of Researcher /person taking the consent\_\_\_\_\_

Date \_\_\_\_\_

Day/month/year

Print Name of Principal Investigator\_\_\_\_\_

Signature of Principal Investigator\_\_\_\_\_

Date \_\_\_\_

Day/month/year

[Note: This document should be signed by the PI / Researchers at the time of taking consent of participants]